Armistice Capital, LLC 13D and 13G filings for Travere Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 11:17 am Purchase | 2026-03-31 | 13G | TRAVERE THERAPEUTICS INC TVTX | Armistice Capital, LLC | 4,897,417 5.270% | 1,133,526 (+30.12%) | Filing |
| 2026-02-17 9:38 pm Sale | 2025-12-31 | 13G | TRAVERE THERAPEUTICS INC TVTX | Armistice Capital, LLC | 3,763,891 4.210% | -2,960,109 (-44.02%) | Filing |
| 2025-11-14 6:28 pm Sale | 2025-09-30 | 13G | TRAVERE THERAPEUTICS INC TVTX | Armistice Capital, LLC | 6,724,000 7.520% | -2,152,000 (-24.25%) | Filing |
| 2025-05-15 3:13 pm Purchase | 2025-03-31 | 13G | TRAVERE THERAPEUTICS INC TVTX | Armistice Capital, LLC | 8,872,000 9.990% | 1,514,000 (+20.58%) | Filing |
| 2025-02-14 5:22 pm Sale | 2024-12-31 | 13G | TRAVERE THERAPEUTICS INC TVTX | Armistice Capital, LLC | 7,358,000 9.620% | -290,000 (-3.79%) | Filing |
| 2024-11-14 5:13 pm Purchase | 2024-09-30 | 13G | TRAVERE THERAPEUTICS INC TVTX | Armistice Capital, LLC | 7,648,000 10.000% | 264,000 (+3.58%) | Filing |
| 2024-02-14 2:35 pm Purchase | 2023-12-31 | 13G | TRAVERE THERAPEUTICS INC TVTX | Armistice Capital, LLC | 7,384,000 9.830% | 972,000 (+15.16%) | Filing |
| 2023-02-14 1:39 pm Purchase | 2022-12-31 | 13G | TRAVERE THERAPEUTICS INC TVTX | Armistice Capital, LLC | 6,412,000 9.990% | 2,334,000 (+57.23%) | Filing |
| 2022-02-14 5:22 pm Purchase | 2021-12-31 | 13G | TRAVERE THERAPEUTICS INC TVTX | Armistice Capital, LLC | 4,078,000 6.700% | 4,078,000 (New Position) | Filing |